De-novo and acquired resistance to immune checkpoint targeting

2017/12/01 by Nicholas Syn, Nicholas L Syn, Michele W.L. Teng +5 · 1 citation
Biochemistry, Genetics and Molecular Biology · Medicine · #CAR-T cell therapy research #Cancer Genomics and Diagnostics #Cancer Immunotherapy and Biomarkers

paper · doi:10.1016/s1470-2045(17)30607-1

crossref issued 2017/12/01 · crossref published 2017/12/01 · crossref published-print 2017/12/01 · openalex publication_date 2017/12/01 · crossref created 2017/12/01 · openalex created_date 2025/10/10 · crossref deposited 2025/10/26 · crossref indexed 2026/07/09 · openalex updated_date 2026/07/29

Citations

• Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
• Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
• Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

Cited by

• Immune system [wikipedia]